Synapse - Elizabeth Cruz

Results (7)

Patient portals to elicit essential patient-reported elements of communication supporting person-centered oncologic care: A pilot study of the PERSON Approach

Journal Article

Epstein, A. S.; Knezevic, A.; Romano, D. R.; Hoque, A.; Raj, N.; Reidy, D.; Rosa, W. E.; Cruz, E.; Calderon, C.; O'Shaughnessy, S.; more...
JCO Clinical Cancer Informatics (2023)

Fulltext@MSK | Save

Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well- differentiated neuroendocrine tumors (WDNETs)

Meeting Abstract

Raj, N.; Cruz, E.; Chou, J.; Capanu, M.; DeMore, A.; Hauser, H.; Heffernan, O.; Le, T.; Saltz, L.; Reidy-Lagunes, D.
Pancreas (2022)

Fulltext@MSK | Save

A randomized trial evaluating patient experience and preference between octreotide long-acting release and lanreotide for treatment of well-differentiated neuroendocrine tumors

Journal Article

Raj, N.; Cruz, E.; O'Shaughnessy, S.; Calderon, C.; Chou, J. F.; Capanu, M.; Heffernan, O.; DeMore, A.; Punn, S.; Le, T.; more...
JCO Oncology Practice (2022)

Fulltext@MSK | Save

Navigating a newly diagnosed cancer through clinician-facilitated discussions of health-related patient values: A qualitative analysis

Journal Article

Lynch, K. A.; Bernal, C.; Romano, D. R.; Shin, P.; Nelson, J. E.; Okpako, M.; Anderson, K.; Cruz, E.; Desai, A. V.; Klimek, V. M.; more...
BMC Palliative Care (2022)

Fulltext@MSK | Save

Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs)